AAN 2017 DAILY REPORT

 

Report from the American Academy of Neurology annual meeting, Boston MA, 22-28 April  2017

Thursday Edition
Wednesday Edition
Tuesday Edition


CONGRESS HIGHLIGHTS – THURSDAY EDITION
Ocrelizumab
Teriflunomide
Dimethyl fumarate
Fingolimod
Alemtuzumab
Natalizumab
Cladribine

Ocrelizumab: A post-hoc analysis of data from the newly-published OPERA trials I and II (Hauser et al. N Engl J Med 2017;376:221-34) reported that ocrelizumab reduced the cumulative probability of relapse vs. interferon-beta-1a by week 8 of treatment; the annualized relapse rate (ARR) from baseline to week 8 was also significantly lower (0.12 vs. 0.27) (Hauser et al. AAN 2017; abstract S31.002).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page